Satoh T - Search Results

1

Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.

Yamada Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S. Yamada Y, et al. Among authors: satoh t. BMC Res Notes. 2016 Oct 18;9(1):471. doi: 10.1186/s13104-016-2279-9. BMC Res Notes. 2016. PMID: 27756383 Free PMC article.

2

Cancer core distribution in patients diagnosed by extended transperineal prostate biopsy.

Satoh T, Matsumoto K, Fujita T, Tabata K, Okusa H, Tsuboi T, Arakawa T, Irie A, Egawa S, Baba S. Satoh T, et al. Urology. 2005 Jul;66(1):114-8. doi: 10.1016/j.urology.2005.01.051. Urology. 2005. PMID: 15992910

3

Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer.

Tetzlaff MT, Teh BS, Timme TL, Fujita T, Satoh T, Tabata K, Mai WY, Vlachaki MT, Amato RJ, Kadmon D, Miles BJ, Ayala G, Wheeler TM, Aguilar-Cordova E, Thompson TC, Butler EB. Tetzlaff MT, et al. Among authors: satoh t. Technol Cancer Res Treat. 2006 Feb;5(1):23-36. doi: 10.1177/153303460600500104. Technol Cancer Res Treat. 2006. PMID: 16417399 Free article. Review.

4

[8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].

Tabata K, Satoh T, Matsumoto K, Fujita T, Irie A, Iwamura M, Yanagisawa N, Matsuda D, Muramoto M, Kadowaki K, Suyama K, Shoji K, Koh H, Kawakami T, Okayasu I, Egawa S, Baba S. Tabata K, et al. Among authors: satoh t. Nihon Hinyokika Gakkai Zasshi. 2006 Jul;97(5):712-8. doi: 10.5980/jpnjurol1989.97.712. Nihon Hinyokika Gakkai Zasshi. 2006. PMID: 16898594 Free article. Clinical Trial. Japanese.

5

[Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy].

Kimura M, Satoh T, Okazaki M, Tabata K, Tsuboi T, Hyodo T, Yokoyama E, Matsumoto K, Soh S, Iwamura M, Hayakawa K, Bab S. Kimura M, et al. Among authors: satoh t. Nihon Hinyokika Gakkai Zasshi. 2008 Jan;99(1):22-8. doi: 10.5980/jpnjurol1989.99.22. Nihon Hinyokika Gakkai Zasshi. 2008. PMID: 18260344 Free article. Japanese.

6

Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer.

Tabata K, Watanabe M, Naruishi K, Edamura K, Satoh T, Yang G, Abdel Fattah E, Wang J, Goltsov A, Floryk D, Soni SD, Kadmon D, Thompson TC. Tabata K, et al. Among authors: satoh t. Prostate Cancer Prostatic Dis. 2009;12(3):301-9. doi: 10.1038/pcan.2008.57. Epub 2008 Dec 23. Prostate Cancer Prostatic Dis. 2009. PMID: 19104507

7

Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.

Ishiyama H, Kitano M, Satoh T, Kotani S, Uemae M, Matsumoto K, Okusa H, Tabata K, Baba S, Hayakawa K. Ishiyama H, et al. Among authors: satoh t. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):23-8. doi: 10.1016/j.ijrobp.2008.11.006. Epub 2009 Feb 23. Int J Radiat Oncol Biol Phys. 2009. PMID: 19243900

8

Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.

Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S. Satoh T, et al. Cancer. 2009 Aug 1;115(15):3468-74. doi: 10.1002/cncr.24404. Cancer. 2009. PMID: 19484786 Free article. Clinical Trial.

9

Cost comparison of curative therapies for localized prostate cancer in Japan: a single-institution experience.

Satoh T, Ishiyama H, Matsumoto K, Tabata K, Kitano M, Iwamura M, Kimura M, Minamida S, Yamashita H, Matsuda D, Kotani S, Niibe Y, Uemae M, Hayakawa K, Baba S. Satoh T, et al. Jpn J Radiol. 2009 Nov;27(9):348-54. doi: 10.1007/s11604-009-0356-x. Epub 2009 Nov 27. Jpn J Radiol. 2009. PMID: 19943145

10

A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.

Matsumoto K, Noguchi M, Satoh T, Tabata K, Fujita T, Iwamura M, Yamada A, Komatsu N, Baba S, Itoh K. Matsumoto K, et al. Among authors: satoh t. BJU Int. 2011 Sep;108(6):831-8. doi: 10.1111/j.1464-410X.2010.09933.x. Epub 2010 Dec 16. BJU Int. 2011. PMID: 21166757 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,754 results

Search Page